KEVZARA: payments to doctors
Payments that named KEVZARA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $9.3M
- Providers
- 4,911
- Transactions
- 38,579
- Average per transaction
- $240
The per-transaction average — $240 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 4,911 providers the average total is $1,885, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $7,286,300 | 78.7% |
| Regeneron Healthcare Solutions, Inc. | $1,351,005 | 14.6% |
| Regeneron | $261,748 | 2.8% |
| Sanofi-aventis U.S. LLC | $221,667 | 2.4% |
| Sanofi US Services Inc. | $134,219 | 1.5% |